Pnd57 - The Cost-Effectiveness of Alemtuzumab in the Management of Relapse-Remitting Multiple Sclerosis in Italy
Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.2023
Full Text
Open PDFAbstract
Available in full text
Date
October 1, 2018
Authors
Publisher
Elsevier BV